On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

BACKGROUND: Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone as first-line treatment in advanced lung squamous cell carcinoma (LUSC) in the phase III trial (CameL-sq), which has become an option of standar...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Tao, Chen, Jianhua, Xu, Xingxiang, Cheng, Ying, Chen, Gongyan, Pan, Yueyin, Fang, Yong, Wang, Qiming, Huang, Yunchao, Yao, Wenxiu, Wang, Rui, Li, Xingya, Zhang, Wei, Zhang, Yanjun, Hu, Sheng, Guo, Renhua, Shi, Jianhua, Wang, Zhiwu, Cao, Peiguo, Wang, Donglin, Fang, Jian, Luo, Hui, Geng, Yi, Xing, Chunyan, Lv, Dongqing, Zhang, Yiping, Yu, Junyan, Cang, Shundong, Zhang, Yaxi, Zhang, Jiao, Yang, Zeyu, Shi, Wei, Zou, Jianjun, Zhou, Caicun, Ren, Shengxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722280/
https://www.ncbi.nlm.nih.gov/pubmed/34980131
http://dx.doi.org/10.1186/s12943-021-01479-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722280/
https://www.ncbi.nlm.nih.gov/pubmed/34980131
http://dx.doi.org/10.1186/s12943-021-01479-4

Ejemplares similares